Insider Buying: Enovis (NYSE:ENOV) CEO Purchases 13,035 Shares

Enovis Corporation (NYSE:ENOV) CEO Damien Mcdonald purchased 13,035 shares of Enovis stock in a transaction on Friday, September 4th. The stock was bought at an average price of $19.15 per share, for a total transaction of $249,620.25. Following the transaction, the chief executive officer directly owned 247,077 shares in the company, valued at approximately $4,731,524.55. The trade was a 5.57% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Enovis Trading Down 4.2%

Shares of ENOV stock traded down $0.82 on Friday, hitting $18.58. The company had a trading volume of 1,886,327 shares, compared to its average volume of 1,200,013. Enovis Corporation has a twelve month low of $18.52 and a twelve month high of $34.28. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98. The firm has a market cap of $1.07 billion, a P/E ratio of 5.79 and a beta of 1.31. The stock’s 50-day moving average is $25.50 and its two-hundred day moving average is $24.20.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.05. The company had revenue of $582.78 million for the quarter, compared to analyst estimates of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The firm’s quarterly revenue was up 3.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities research analysts anticipate that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ENOV has been the topic of a number of analyst reports. Wells Fargo & Company reduced their price objective on shares of Enovis from $39.00 to $33.00 and set an “overweight” rating on the stock in a research note on Wednesday. Zacks Research upgraded shares of Enovis from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 29th. Citizens Jmp cut their price target on shares of Enovis from $55.00 to $47.00 and set a “market outperform” rating on the stock in a research report on Wednesday. BTIG Research decreased their price target on Enovis from $40.00 to $36.00 and set a “buy” rating for the company in a report on Tuesday. Finally, Citigroup reiterated a “market outperform” rating on shares of Enovis in a report on Wednesday. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $40.38.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Arax Advisory Partners acquired a new stake in Enovis in the fourth quarter worth $29,000. Allworth Financial LP acquired a new position in shares of Enovis during the second quarter valued at about $36,000. EverSource Wealth Advisors LLC raised its holdings in shares of Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares during the period. Public Employees Retirement System of Ohio bought a new position in shares of Enovis during the 2nd quarter worth about $48,000. Finally, Danske Bank A S bought a new position in shares of Enovis during the 3rd quarter worth about $64,000. 98.45% of the stock is owned by institutional investors.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.